Stock Information

• ImmunityBio's Anktiva Could See More Upside: My Updated Thoughts On Expansion
  Tue, Mar 17, 2026 4:39 PM
• ImmunityBio shares are trading higher after the company announced that the National Comprehensive Cancer Network has updated its 2026 Clinical Practice Guidelines in Oncology for Bladder Cancer to include ANKTIVA, in combination with Bacillus Calmette-Guérin, for the treatment of patients with BCG-unresponsive non-muscle invasive bladder cancer with papillary-only disease.
  Tue, Mar 17, 2026 8:27 AM
• The National Comprehensive Cancer Network Updates Its 2026 NCCN Clinical Practice Guidelines In Oncology For Bladder Cancer To Include Immunitybio's Anktiva In Combination With Bacillus Calmette-guérin (BCG) For BCG-Unresponsive Non-Muscle Invasive Bladder Cancer With Papillary-Only Disease
  Tue, Mar 17, 2026 7:36 AM
• ImmunityBio shares are trading higher after the company announced successful completion of manufacturing engineering programs, NK2022 and NK2023, for its M-ceNK memory cytokine-enhanced natural killer cell therapy platform. Also, the Phase I program combining M-ceNK with ANKTIVA has enrolled 74 subjects.
  Fri, Mar 13, 2026 12:48 PM
• Why Is ImmunityBio Stock Soaring On Friday?
  Fri, Mar 13, 2026 10:44 AM
• El Pollo Loco Posts Upbeat Q4 Results, Joins Kyivstar Group, American Public Education And Other Big Stocks Moving Higher On Friday
  Fri, Mar 13, 2026 9:59 AM
• ImmunityBio Achieves Large Scale NK Cell Production And Cryopreservation Milestone, Generates Up To 5B Cells Per Apheresis And Advances M-ceNK Platform With Phase 1 Safety Data
  Fri, Mar 13, 2026 7:34 AM
• BTIG Assumes ImmunityBio at Buy, Announces Price Target of $13
  Thu, Mar 12, 2026 6:56 AM

Financial data not available